Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
4.31B
Market cap4.31B
Price-Earnings ratio
-22.65
Price-Earnings ratio-22.65
Dividend yield
Dividend yield
Average volume
2.29M
Average volume2.29M
High today
$94.00
High today$94.00
Low today
$87.71
Low today$87.71
Open price
$92.13
Open price$92.13
Volume
1.65M
Volume1.65M
52 Week high
$151.02
52 Week high$151.02
52 Week low
$11.28
52 Week low$11.28

Stock Snapshot

As of today, Celcuity(CELC) shares are valued at $88.28. The company's market cap stands at 4.31B, with a P/E ratio of -22.65.

During the trading session on 2026-06-06, Celcuity(CELC) shares reached a daily high of $94.00 and a low of $87.71. At a current price of $88.28, the stock is +0.7% higher than the low and still -6.1% under the high.

Trading volume for Celcuity(CELC) stock has reached 1.65M, versus its average volume of 2.29M.

Over the past 52 weeks, Celcuity(CELC) stock has traded between a high of $151.02 and a low of $11.28.

Over the past 52 weeks, Celcuity(CELC) stock has traded between a high of $151.02 and a low of $11.28.

CELC News

Simply Wall St 2d
Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets - simplywall.st

...

Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets - simplywall.st
TipRanks 3d
Celcuity price target lowered to $171 from $189 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Celcuity (CELC) to $171 from $189 and keeps a Buy rating on the shares following ASCO data from VIKTORIA-1 study...

Benzinga 4d
What's Going On With Celcuity Stock On Tuesday?

Gedatolisib Outperformed Comparator Regimen According to the company, the gedatolisib-triplet regimen delivered a statistically significant improvement in prog...

What's Going On With Celcuity Stock On Tuesday?

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

More CELC News

TipRanks 5d
Celcuity highlights positive Phase 3 gedatolisib breast cancer data

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.